Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACOTAS: Cardiovascular events with trifluridine/tipiracil ± oxaliplatin in colorectal/oesogastric adenocarcinoma
2020-004636-25Phase 2Completed
- Sponsor
- GERCOR
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trifluridine + tipiracil in colorectal adenocarcinoma and Gastroesophageal junction adenocarcinoma (GEJA) (2 arms), sponsored by GERCOR. Primary endpoint: Rate of cardiovascular events at 3 months. Started Dec 2020; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal adenocarcinomaGastroesophageal junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on 2020-004636-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004636-25.